NorthWest Biotherapeutics Inc (NWBO)

[exwannabe]

We will be over $100 in 5 years, or even a lot sooner, considering rapid tumor shrinkage trials.

Tumor shrinkage (ORR) is a very normal endpoint in early stage trials. When DCVax has failed to ever show any, longs said it does not matter. And now you cheer it. See anything wrong here?

Management can divide up indications among BP partners then run a bunch of quick trials in parallel.

Having multiple vendors is a great idea for keeping prices reasonable. Maybe the FDA should require it. Not sure why any BP (or smaller player) would want it though.

With Flaskworks in place the greenfield market will be quickly cornered by DCVax

There have been several automated cellular manufacturing systems from vendors in operation for a few years now. Flaskworks Eden, it it ever exists, is a "me too".